Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase.

Laponogov I, Pan XS, Veselkov DA, Skamrova GB, Umrekar TR, Fisher LM, Sanderson MR.

Nat Commun. 2018 Jul 3;9(1):2579. doi: 10.1038/s41467-018-05005-x.

2.

Speech and Communicative Participation in Patients With Facial Paralysis.

Kim JH, Fisher LM, Reder L, Hapner ER, Pepper JP.

JAMA Otolaryngol Head Neck Surg. 2018 Aug 1;144(8):686-693. doi: 10.1001/jamaoto.2018.0649.

3.

Abnormal Cochleovestibular Anatomy and Hearing Outcomes: Pediatric Patients with a Questionable Cochleovestibular Nerve Status May Benefit from Cochlear Implantation and/or Hearing Aids.

Kari E, Go JL, Loggins J, Emmanuel N, Fisher LM.

Audiol Neurootol. 2018;23(1):48-57. doi: 10.1159/000488793. Epub 2018 Jun 22.

PMID:
29936507
4.

Early Communication Development of Children with Auditory Brainstem Implants.

Eisenberg LS, Hammes Ganguly D, Martinez AS, Fisher LM, Winter ME, Glater JL, Schrader DK, Loggins J, Wilkinson EP; Los Angeles Pediatric ABI Team.

J Deaf Stud Deaf Educ. 2018 Jul 1;23(3):249-260. doi: 10.1093/deafed/eny010.

5.

Prevalence of Hearing Loss and Hearing Care Use Among Asian Americans: A Nationally Representative Sample.

Choi JS, Kari E, Friedman RA, Fisher LM.

Otol Neurotol. 2018 Feb;39(2):158-167. doi: 10.1097/MAO.0000000000001668.

PMID:
29315179
6.

Age-related histologic and biochemical changes in auricular and septal cartilage.

Riedler KL, Shokrani A, Markarian A, Fisher LM, Pepper JP.

Laryngoscope. 2017 Nov;127(11):E399-E407. doi: 10.1002/lary.26807. Epub 2017 Aug 28.

PMID:
28846132
7.

Initiation, dropout, and outcome from evidence-based psychotherapies in a VA PTSD outpatient clinic.

Niles BL, Polizzi CP, Voelkel E, Weinstein ES, Smidt K, Fisher LM.

Psychol Serv. 2018 Nov;15(4):496-502. doi: 10.1037/ser0000175. Epub 2017 Jul 10.

PMID:
28691851
8.

Compound heterozygous mutations in MASP1 in a deaf child with absent cochlear nerves.

Kari E, Schrauwen I, Llaci L, Fisher LM, Go JL, Naymik M, Knowles JA, Huentelman MJ, Friedman RA.

Neurol Genet. 2017 May 11;3(3):e153. doi: 10.1212/NXG.0000000000000153. eCollection 2017 Jun. No abstract available.

9.

Assessing the Benefit-Risk Profile for Pediatric Implantable Auditory Prostheses.

Fisher LM, Martinez AS, Richmond FJ, Krieger MD, Wilkinson EP, Eisenberg LS.

Ther Innov Regul Sci. 2018 Sep;52(5):669-679. doi: 10.1177/2168479017741111. Epub 2017 Nov 29.

10.

Initial Results of a Safety and Feasibility Study of Auditory Brainstem Implantation in Congenitally Deaf Children.

Wilkinson EP, Eisenberg LS, Krieger MD, Schwartz MS, Winter M, Glater JL, Martinez AS, Fisher LM, Shannon RV; Los Angeles Pediatric ABI Team.

Otol Neurotol. 2017 Feb;38(2):212-220. doi: 10.1097/MAO.0000000000001287.

11.

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.

Laponogov I, Pan XS, Veselkov DA, Cirz RT, Wagman A, Moser HE, Fisher LM, Sanderson MR.

Open Biol. 2016 Sep;6(9). pii: 160157.

12.

Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.

Veselkov DA, Laponogov I, Pan XS, Selvarajah J, Skamrova GB, Branstrom A, Narasimhan J, Prasad JV, Fisher LM, Sanderson MR.

Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):488-96. doi: 10.1107/S2059798316001212. Epub 2016 Mar 24.

13.

Sentence Recognition in Quiet and Noise by Pediatric Cochlear Implant Users: Relationships to Spoken Language.

Eisenberg LS, Fisher LM, Johnson KC, Ganguly DH, Grace T, Niparko JK; CDaCI Investigative Team.

Otol Neurotol. 2016 Feb;37(2):e75-81. doi: 10.1097/MAO.0000000000000910.

14.

Device Life of Two Generations of Provox Voice Prostheses.

Thylur DS, Villegas BC, Fisher LM, Sinha UK, Kokot N.

Ann Otol Rhinol Laryngol. 2016 Jun;125(6):501-7. doi: 10.1177/0003489415624701. Epub 2016 Jan 7.

PMID:
26747630
15.

Regulatory and funding strategies to develop a safety study of an auditory brainstem implant in young children who are deaf.

Fisher LM, Eisenberg LS, Krieger M, Wilkinson EP, Shannon RV; Los Angeles Pediatric ABI Team.

Ther Innov Regul Sci. 2015 Sep;49(5):659-665. No abstract available.

16.

Prognostic implications of and audiometric evidence for hearing fluctuation in Meniere's disease.

Hoa M, Friedman RA, Fisher LM, Derebery MJ.

Laryngoscope. 2015 Dec;125 Suppl 12:S1-12. doi: 10.1002/lary.25579. Epub 2015 Sep 7.

PMID:
26343803
17.

A Prospective Longitudinal Study of U.S. Children Unable to Achieve Open-Set Speech Recognition 5 Years After Cochlear Implantation.

Barnard JM, Fisher LM, Johnson KC, Eisenberg LS, Wang NY, Quittner AL, Carson CM, Niparko JK; CDaCI Investigative Team.

Otol Neurotol. 2015 Jul;36(6):985-92. doi: 10.1097/MAO.0000000000000723.

18.

An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease.

Derebery MJ, Fisher LM, Voelker CC, Calzada A.

Otol Neurotol. 2014 Oct;35(9):1515-21. doi: 10.1097/MAO.0000000000000566.

PMID:
25203561
19.

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S, Kalamarides M.

Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10.

20.

Engineering goals for future thoracic endografts-how can we make them more effective?

Weidman JM, Desai M, Iftekhar A, Boyle K, Greengard JS, Fisher LM, Thomas RL, Zannetti S.

Prog Cardiovasc Dis. 2013 Jul-Aug;56(1):92-102. doi: 10.1016/j.pcad.2013.05.001. Epub 2013 Jun 24. Review.

PMID:
23993242
21.

Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport.

Laponogov I, Veselkov DA, Crevel IM, Pan XS, Fisher LM, Sanderson MR.

Nucleic Acids Res. 2013 Nov;41(21):9911-23. doi: 10.1093/nar/gkt749. Epub 2013 Aug 21.

22.

Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.

Arnoldi E, Pan XS, Fisher LM.

Nucleic Acids Res. 2013 Nov;41(20):9411-23. doi: 10.1093/nar/gkt696. Epub 2013 Aug 12.

23.

Genetic evidence for an ethnic diversity in the susceptibility to Ménière's disease.

Ohmen JD, White CH, Li X, Wang J, Fisher LM, Zhang H, Derebery MJ, Friedman RA.

Otol Neurotol. 2013 Sep;34(7):1336-41. doi: 10.1097/MAO.0b013e3182868818.

PMID:
23598705
24.

The relationship between high-frequency pure-tone hearing loss, hearing in noise test (HINT) thresholds, and the articulation index.

Vermiglio AJ, Soli SD, Freed DJ, Fisher LM.

J Am Acad Audiol. 2012 Nov-Dec;23(10):779-88. doi: 10.3766/jaaa.23.10.4.

PMID:
23169195
25.

GRM7 variants associated with age-related hearing loss based on auditory perception.

Newman DL, Fisher LM, Ohmen J, Parody R, Fong CT, Frisina ST, Mapes F, Eddins DA, Robert Frisina D, Frisina RD, Friedman RA.

Hear Res. 2012 Dec;294(1-2):125-32. doi: 10.1016/j.heares.2012.08.016. Epub 2012 Oct 25.

26.

Oral steroid treatment for hearing improvement in Ménière's disease and endolymphatic hydrops.

Fisher LM, Derebery MJ, Friedman RA.

Otol Neurotol. 2012 Dec;33(9):1685-91. doi: 10.1097/MAO.0b013e31826dba83.

PMID:
23047260
27.

Cochlear implant patients' localization using interaural level differences exceeds that of untrained normal hearing listeners.

Aronoff JM, Freed DJ, Fisher LM, Pal I, Soli SD.

J Acoust Soc Am. 2012 May;131(5):EL382-7. doi: 10.1121/1.3699017.

28.

Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Carrasquilla G, Barón C, Monsell EM, Cousin M, Walter V, Lefèvre G, Sander O, Fisher LM.

Am J Trop Med Hyg. 2012 Jan;86(1):75-83. doi: 10.4269/ajtmh.2012.11-0192.

29.

Middle fossa decompression for hearing preservation: a review of institutional results and indications.

Slattery WH, Hoa M, Bonne N, Friedman RA, Schwartz MS, Fisher LM, Brackmann DE.

Otol Neurotol. 2011 Aug;32(6):1017-24. doi: 10.1097/MAO.0b013e3182267eb7.

PMID:
21725256
30.

The effect of different cochlear implant microphones on acoustic hearing individuals' binaural benefits for speech perception in noise.

Aronoff JM, Freed DJ, Fisher LM, Pal I, Soli SD.

Ear Hear. 2011 Jul-Aug;32(4):468-84. doi: 10.1097/AUD.0b013e31820dd3f0.

31.

Structural basis of gate-DNA breakage and resealing by type II topoisomerases.

Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, Sanderson MR.

PLoS One. 2010 Jun 28;5(6):e11338. doi: 10.1371/journal.pone.0011338. Erratum in: PLoS One. 2010;5(7) doi: 10.1371/annotation/deacc2fd-665b-4736-b668-dc69a38bb4f9.

32.

Outcomes of endolymphatic shunt surgery for Ménière's disease: comparison with intratympanic gentamicin on vertigo control and hearing loss.

Derebery MJ, Fisher LM, Berliner K, Chung J, Green K.

Otol Neurotol. 2010 Jun;31(4):649-55. doi: 10.1097/MAO.0b013e3181dd13ac.

PMID:
20431498
33.

Radiation therapy for the treatment of vestibular schwannoma: a critical evaluation of the state of the literature.

Bassim MK, Berliner KI, Fisher LM, Brackmann DE, Friedman RA.

Otol Neurotol. 2010 Jun;31(4):567-73. doi: 10.1097/MAO.0b013e3181d8d3ad. Review.

PMID:
20300044
34.

Bone-anchored hearing aid subjective benefit for unilateral deafness.

House JW, Kutz JW Jr, Chung J, Fisher LM.

Laryngoscope. 2010 Mar;120(3):601-7. doi: 10.1002/lary.20802.

PMID:
20131363
35.

Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.

Fisher LM, Doherty JK, Lev MH, Slattery WH.

Otol Neurotol. 2009 Sep;30(6):835-41. doi: 10.1097/MAO.0b013e3181b2364c.

PMID:
19704365
36.

Doctors trading places: the Isolated Practitioner Peer Support Scheme.

Moran JG, Page SL, Birden HH, Fisher LM, Hancock NJ.

Med J Aust. 2009 Jul 20;191(2):78-80.

PMID:
19619090
37.

Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.

Pan XS, Gould KA, Fisher LM.

Antimicrob Agents Chemother. 2009 Sep;53(9):3822-31. doi: 10.1128/AAC.00113-09. Epub 2009 Jun 29.

38.

Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.

Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR.

Nat Struct Mol Biol. 2009 Jun;16(6):667-9. doi: 10.1038/nsmb.1604. Epub 2009 May 17.

PMID:
19448616
39.

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.

Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM.

J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.

PMID:
19147516
40.

The difficult case of crystallization and structure solution for the ParC55 breakage-reunion domain of topoisomerase IV from Streptococcus pneumoniae.

Sohi MK, Veselkov DA, Laponogov I, Pan XS, Fisher LM, Sanderson MR.

PLoS One. 2008 Sep 12;3(9):e3201. doi: 10.1371/journal.pone.0003201.

41.

Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage.

Pan XS, Dias M, Palumbo M, Fisher LM.

Nucleic Acids Res. 2008 Oct;36(17):5516-29. doi: 10.1093/nar/gkn539. Epub 2008 Aug 22.

42.

The effect of famciclovir on delayed facial paralysis after acoustic tumor resection.

Brackmann DE, Fisher LM, Hansen M, Halim A, Slattery WH.

Laryngoscope. 2008 Sep;118(9):1617-20. doi: 10.1097/MLG.0b013e3181788d5d.

PMID:
18596563
43.

Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.

Fisher LM, Pan XS.

Methods Mol Med. 2008;142:11-23. doi: 10.1007/978-1-59745-246-5_2.

PMID:
18437302
44.

Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2.

Fisher LM, Doherty JK, Lev MH, Slattery WH 3rd.

Otol Neurotol. 2007 Dec;28(8):1083-90. Erratum in: Otol Neurotol. 2008 Sep;29(6):885.

PMID:
18043434
45.

Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.

Richter SN, Giaretta G, Comuzzi V, Leo E, Mitchenall LA, Fisher LM, Maxwell A, Palumbo M.

Nucleic Acids Res. 2007;35(18):6075-85. Epub 2007 Aug 30.

46.

Evaluation of facial function with a questionnaire: reliability and validity.

Cullen RD, House JW, Brackmann DE, Luxford WM, Fisher LM.

Otol Neurotol. 2007 Aug;28(5):719-22.

PMID:
17554227
47.

Facial nerve function after translabyrinthine vestibular schwannoma surgery.

Brackmann DE, Cullen RD, Fisher LM.

Otolaryngol Head Neck Surg. 2007 May;136(5):773-7.

PMID:
17478214
48.

Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients.

Slattery WH 3rd, Fisher LM, Hitselberger W, Friedman RA, Brackmann DE.

J Neurosurg. 2007 Apr;106(4 Suppl):255-60.

PMID:
17465357
49.

Breakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone target.

Laponogov I, Veselkov DA, Sohi MK, Pan XS, Achari A, Yang C, Ferrara JD, Fisher LM, Sanderson MR.

PLoS One. 2007 Mar 21;2(3):e301.

50.

First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.

Aubry A, Fisher LM, Jarlier V, Cambau E.

Biochem Biophys Res Commun. 2006 Sep 15;348(1):158-65. Epub 2006 Jul 13.

PMID:
16876125

Supplemental Content

Loading ...
Support Center